The latest Investing Matters Podcast episode featuring financial educator and author Jared Dillian has been released. Listen here.

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksAstrazeneca Share News (AZN)

Share Price Information for Astrazeneca (AZN)

London Stock Exchange
Share Price is delayed by 15 minutes
Get Live Data
Share Price: 12,174.00
Bid: 12,170.00
Ask: 12,174.00
Change: -72.00 (-0.59%)
Spread: 4.00 (0.033%)
Open: 12,240.00
High: 12,306.00
Low: 12,170.00
Prev. Close: 12,246.00
AZN Live PriceLast checked at -

Watchlists are a member only feature

Login to your account

Alerts are a premium feature

Login to your account

UPDATE 4-Too soon to say if Britons can take summer holiday abroad, says UK's Johnson

Mon, 05th Apr 2021 07:49

* Summer holiday abroad? Too early to know, UK says

* UK to have traffic light system for travel

* International travel will not start before May 17

* England's economy to start to reopen from April 12

* Johnson to raise a pint on April 12
(Adds quotes)

By Kate Holton, Alistair Smout and Elizabeth Piper

LONDON, April 5 (Reuters) - British Prime Minister Boris
Johnson said on Monday it was too soon to say whether
international summer holidays can go ahead this year, a remark
suggesting a planned reopening of outbound travel could be
pushed back beyond May 17.

Britons are among Europe's highest spending tourists so the
fortunes of the continent's summer season and the travel
industry, hit hard by restrictions imposed on travel because of
the COVID-19 pandemic, will depend on when tourists can return
to the beaches, cafes and tavernas of southern Europe.

Britain plans to use a traffic-light risk system for
countries once non-essential international travel resumes, but
the government said it was too early to say which countries
could be given the green light that would only require
coronavirus tests before and after travel.

"Taking into account the latest situation with (coronavirus)
variants and the evidence about the efficacy of vaccines against
them, we will confirm in advance whether non-essential
international travel can resume on 17 May, or whether we will
need to wait longer before lifting the outbound travel
restriction," a government review said.

Johnson told a news conference he was hopeful that
non-essential international travel would restart from May 17,
but that he did not want to underestimate the growing number of
COVID-19 cases elsewhere.

"Obviously we are hopeful that we can get going from May
17th, but I do not wish to give hostages to fortune or to
underestimate the difficulties that we are seeing in some of the
destination countries that people might want to go to," he said.

British media suggested countries on the green list,
requiring testing before and after travel, could include
Portugal, Malta, Israel, the United Arab Emirates and the United
States.

Under Johnson's original plan, international travel would
not resume until May 17 at the earliest. Countries on the amber
list would require self-isolation. Those on the red list would
require quarantine.

Airlines such as easyJet, Ryanair and
British Airways, plus holiday groups such as TUI
, hope to avoid a second lost summer but COVID-19
cases have risen in continental Europe.

Johnson said a planned reopening of the economy could take
place next week, with the opening of all shops, gyms,
hairdressers and outdoor hospitality areas in England.

VACCINE PASSPORTS

With the vaccine programme rolling out rapidly across
Britain and infection numbers falling, Johnson said England
could proceed to Stage 2 of his roadmap out of lockdown from
April 12.

"On Monday the 12th, I will be going to the pub myself - and
cautiously but irreversibly raising a pint of beer to my lips,"
Johnson said.

Britain said people should continue to work from home where
they can and minimise domestic travel.

Johnson also confirmed that the government was looking at a
COVID-19 status certification system, or vaccine passport, to
help reopen larger events and to travel.

"I want to stress that there are complicated, ethical, and
practical issues... raised by the idea of COVID status
certification... using vaccination alone," Johnson said.

"You've got to be very careful in how you handle this and
... don't start a system that's discriminatory."

People will not need vaccine certification for pubs,
hairdressers and shops, Johnson said.
(Editing by Guy Faulconbridge and Timothy Heritage)

More News
12 May 2024 13:25

Pfizer and AstraZeneca announce new investments of nearly $1 billion in France

PARIS, May 12 (Reuters) - Leading healthcare companies Pfizer and AstraZeneca announced on Sunday new investments in France worth a total of nearly $1 billion, ahead of the start of this year's annual 'Choose France' business summit.

Read more
8 May 2024 19:10

Sector movers: Aerospace and Defence, Pharma pace gains

(Sharecast News) - London's main stock market gauges continued to push higher in the middle of the week, even as investors waited on the Bank of England's policy announcement on the following day.

Read more
8 May 2024 17:46

FTSE 100 hits record high, pound slips ahead of BoE verdict

FTSE 100 up 0.5%, FTSE 250 adds 0.4%

*

Read more
8 May 2024 16:36

London close: Stocks rise further ahead of BoE decision

(Sharecast News) - London's stock markets closed with gains on Wednesday, bolstered by a dip in the value of the pound against both the dollar and the euro.

Read more
8 May 2024 09:44

AstraZeneca says withdraws Covid vaccine "for commercial reasons"

(Alliance News) - Drugmaker AstraZeneca PLC said Wednesday that it has withdrawn its Covid vaccine Vaxzevria, one of the first produced in the pandemic, citing "commercial reasons" and a surplus of updated jabs.

Read more
8 May 2024 09:39

LONDON BROKER RATINGS: UBS raises Centrica to 'buy' from 'neutral

(Alliance News) - The following London-listed shares received analyst recommendations Wednesday morning and Tuesday:

Read more
7 May 2024 15:54

Berenberg hikes target price on Astrazeneca

(Sharecast News) - Analysts at Berenberg hiked their target price on drugmaker Astrazeneca from 1,200.0p to 1,300.0p on Tuesday, citing the group was "instilling confidence in the revenues of tomorrow".

Read more
7 May 2024 09:51

LONDON BROKER RATINGS: AstraZeneca target raised; Antofagasta lowered

(Alliance News) - The following London-listed shares received analyst recommendations Tuesday morning and Friday:

Read more
6 May 2024 07:46

AstraZeneca completes collaboration and investment deal with Cellectis

(Alliance News) - AstraZeneca PLC on Monday said it has completed an equity investment in clinical-stage biotechnology company Cellectis, first announced in November.

Read more
3 May 2024 12:17

CORRECT: Angle shares up on assay development deal with AstraZeneca

(Correcting company name in headline)

Read more
3 May 2024 11:50

Angle shares up on assay development deal with AstraZenaca

(Alliance News) - Shares in Angle PLC jumped on Friday, after the company said it has been chosen to develop a prostate cancer assay using its Parsortix technology, opening the door for future clinical study-supporting contracts.

Read more
3 May 2024 07:50

LONDON BRIEFING: InterContinental Hotels makes first-quarter progress

(Alliance News) - London's FTSE 100 is called to open higher on Friday, on the expectation of a softer US jobs report, which could take some sting out of hawkish Federal Reserve interest rate expectations.

Read more
2 May 2024 10:04

AstraZeneca notes positive trial results for Calquence treatment

(Alliance News) - AstraZeneca PLC on Thursday said it observed positive high-level results in the Echo phase 3 trial of its Calquence treatment for previously untreated adult patients with mantle cell lymphoma.

Read more
2 May 2024 07:45

AstraZeneca reports positive results from blood cancer drug trial

(Sharecast News) - AstraZeneca has reported positive results from the use of its Calquence drug in a clinical trial to treat a rare type of blood cancer.

Read more
29 Apr 2024 22:52

J&J, Bristol Myers lose challenges to US drug price negotiation program

April 29 (Reuters) - A U.S. judge on Monday rejected a challenge by Bristol Myers Squibb and Johnson & Johnson to a law requiring them to negotiate the prices of their blockbuster blood clot prevention drugs with the U.S government's Medicare health insurance program or pay heavy penalties.

Read more

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.